| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
| Targets |
Human Endogenous Metabolite; P2X7 receptor
|
|---|---|
| ln Vitro |
The activation of the NLRP3 inflammasome in HGFs is enhanced when ATP disodium trihydrate (5 mM; 1 hour) and LPS (1 μg/mL) are treated together [3]. In a manner that is dependent on caspase-1 activation, ATP disodium trihydrate (2 mM; 0.5-24 hours) causes BMDM to release KC, MIP-2, and IL-1β [4]. Chemotaxis of neutrophils is facilitated by ATP disodium trihydrate [4].
- Cytokine release modulation: Adenosine-5'-Triphosphate (ATP) at concentrations of 10–100 μM significantly enhanced lipopolysaccharide (LPS)-induced interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) release in stimulated whole blood. This effect was abrogated by P2X7 receptor antagonists, indicating P2X7-mediated signaling [1]. - NLRP3 inflammasome activation: In human gingival fibroblasts, ATP (5 mM) co-administered with Porphyromonas gingivalis LPS triggered NLRP3 inflammasome activation, as evidenced by caspase-1 cleavage and IL-1β secretion. This process was inhibited by doxycycline [3]. |
| ln Vivo |
In vivo, mice are protected against bacterial infection by ATP disodium trihydrate (50 mg/kg; ip) [4]. In vivo, ATP disodium trihydrate stimulates the release of KC, MIP-2, and IL-1β as well as the recruitment of neutrophils [4].
- Bacterial infection protection: Intraperitoneal injection of ATP (20 mg/kg) in mice significantly improved survival rates (60% vs. 20% in control) and reduced bacterial burden in a peritoneal Escherichia coli infection model. Protection was abolished in NLRP3 knockout mice, confirming NLRP3-dependent mechanism [4]. |
| Cell Assay |
- Whole blood stimulation: Human whole blood was incubated with LPS (1 μg/mL) and ATP (10–100 μM) for 6 hours. Cytokine levels in supernatants were measured by enzyme-linked immunosorbent assay (ELISA). P2X7 antagonist oxidized ATP (100 μM) blocked ATP-induced cytokine release [1].
- Gingival fibroblast stimulation: Human gingival fibroblasts were primed with LPS (1 μg/mL) for 3 hours, followed by ATP (5 mM) treatment for 30 minutes. Cell lysates were analyzed by Western blot for caspase-1 p20 and IL-1β, while supernatants were assayed for secreted IL-1β [3]. |
| Animal Protocol |
Animal/Disease Models: Fourweeks old Kunming mice (18-22 g)[4]
Doses: 50 mg/kg Route of Administration: intraperitoneal (ip)injection, before bacterial (E. coli) challenge Experimental Results: Protected mice from bacterial infection. - Mouse infection model: ATP was dissolved in sterile saline and administered intraperitoneally (20 mg/kg) to C57BL/6 mice 1 hour before intraperitoneal injection of E. coli (1×10⁹ CFU). Survival was monitored for 72 hours, and peritoneal lavage fluid was cultured to quantify bacterial counts [4]. |
| References |
|
| Additional Infomation |
- Mechanism of action: ATP acts as a danger-associated molecular pattern (DAMP) to activate P2X7 receptors, leading to potassium efflux and NLRP3 inflammasome assembly. This promotes caspase-1 activation and IL-1β/IL-18 secretion, enhancing host defense against bacterial infection [2, 4].
- Immunomodulatory role: Extracellular ATP can either promote inflammation via P2X7 signaling or suppress it through adenosine-mediated pathways, depending on local concentration and cell context [2]. |
| Molecular Formula |
C10H20N5NA2O16P3
|
|---|---|
| Molecular Weight |
605.19
|
| Exact Mass |
550.959
|
| Elemental Analysis |
C, 19.85; H, 3.33; N, 11.57; Na, 7.60; O, 42.30; P, 15.35
|
| CAS # |
51963-61-2
|
| Related CAS # |
ATP disodium salt;987-65-5;ATP;56-65-5;ATP dimagnesium;74804-12-9;ATP disodium salt hydrate;34369-07-8;ATP dipotassium;42373-41-1;ATP ditromethamine;102047-34-7;ATP-13C dilithium;ATP-15N5,d14 dilithium;ATP-d14 dilithium;ATP-15N5 dilithium;ATP-13C10 dilithium
|
| PubChem CID |
22799238
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
176ºC
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
35
|
| Complexity |
772
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)([O-])OP(=O)([O-])OP(=O)([O-])[O-])O)O)N.[Na+].[Na+].[Na+].[Na+]
|
| InChi Key |
MWEQTWJABOLLOS-AZGWGOJFSA-L
|
| InChi Code |
InChI=1S/C10H16N5O13P3.2Na.3H2O/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(26-10)1-25-30(21,22)28-31(23,24)27-29(18,19)20;;;;;/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H,23,24)(H2,11,12,13)(H2,18,19,20);;;3*1H2/q;2*+1;;;/p-2/t4-,6-,7-,10-;;;;;/m1...../s1
|
| Chemical Name |
disodium;[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate
|
| Synonyms |
51963-61-2; ADENOSINE 5'-TRIPHOSPHATE DISODIUM SALT TRIHYDRATE; Adenosine 5'-(tetrahydrogen triphosphate), disodium salt, trihydrate; disodium;[[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate; Adenosine triphosphate disodium salt; Adenosine 5'-triphosphate disodium salt; sodium ((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogentriphosphate trihydrate; Adenosine-5'-triphosphate disodium salt trihydrate;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~250 mg/mL (~413.09 mM)
DMSO :~1 mg/mL (~1.65 mM (<80°C)) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (82.62 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6524 mL | 8.2619 mL | 16.5237 mL | |
| 5 mM | 0.3305 mL | 1.6524 mL | 3.3047 mL | |
| 10 mM | 0.1652 mL | 0.8262 mL | 1.6524 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA